MTOR and nonpapillary renal cell carcinoma: The US Food and Drug Administration has approved agents to treat metastatic ccRCC, including immunotherapeutic drugs, antiangiogenic agents, and mammalian target of rapamycin (mTOR) inhibitors [1, 29].